Nancy MD - Xencor Executive Officer
| XNCR Stock | USD 24.13 0.12 0.50% |
Executive
Nancy MD is Executive Officer of Xencor Inc
| Age | 65 |
| Address | 465 North Halstead Street, Pasadena, CA, United States, 91107 |
| Phone | 626 305 5900 |
| Web | https://www.xencor.com |
Xencor Management Efficiency
The company has return on total asset (ROA) of (0.1524) % which means that it has lost $0.1524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2902) %, meaning that it created substantial loss on money invested by shareholders. Xencor's management efficiency ratios could be used to measure how well Xencor manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/20/2024, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to grow to -0.15. At this time, Xencor's Non Current Assets Total are relatively stable compared to the past year. As of 12/20/2024, Non Currrent Assets Other is likely to grow to about 1.1 M, while Total Current Assets are likely to drop slightly above 326.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Sullivan | Heron Therapeuti | 46 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Elhan CFA | Karyopharm Therapeutics | N/A | |
| Eric Hoefer | Arcus Biosciences | N/A | |
| Timothy Moore | Allogene Therapeutics | 63 | |
| Christian MBA | Sana Biotechnology | 41 | |
| Jerome Bressi | Fate Therapeutics | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Lisa DiPaolo | Karyopharm Therapeutics | N/A | |
| Yuko JD | Sana Biotechnology | N/A | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| Frank Yocca | BioXcel Therapeutics | 68 | |
| Ryan Craig | Heron Therapeuti | N/A | |
| Gary MD | Sana Biotechnology | N/A | |
| Jennifer Jarrett | Arcus Biosciences | 50 | |
| David JD | Allogene Therapeutics | 53 | |
| Friso Postma | BioXcel Therapeutics | N/A | |
| Sohanya MBA | Karyopharm Therapeutics | 41 | |
| Robert Scala | BioXcel Therapeutics | 55 | |
| Snehal Patel | Sana Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 |
Xencor Inc Leadership Team
Elected by the shareholders, the Xencor's board of directors comprises two types of representatives: Xencor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xencor. The board's role is to monitor Xencor's management team and ensure that shareholders' interests are well served. Xencor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xencor's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy MD, Executive Officer | ||
| Dane CFA, Senior Strategy | ||
| Jennifer Sandoz, Senior Resources | ||
| John Desjarlais, Chief Scientific Officer and Sr. VP of Research | ||
| Bart Cornelissen, Senior CFO | ||
| Bassil Dahiyat, Co-Founder, CEO and President and Director | ||
| Kirk RAC, Senior Assurance | ||
| John Kuch, VP of Fin. | ||
| Eric Kowack, Senior Management | ||
| Jeremy Grunstein, Vice President of Business Development | ||
| Celia JD, General VP | ||
| Charles Liles, Associate Relations |
Xencor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xencor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (2.33) % | ||||
| Operating Margin | (5.82) % | ||||
| Current Valuation | 1.23 B | ||||
| Shares Outstanding | 69.98 M | ||||
| Shares Owned By Insiders | 0.89 % | ||||
| Shares Owned By Institutions | 99.11 % | ||||
| Number Of Shares Shorted | 4.46 M | ||||
| Price To Earning | 69.81 X |
Pair Trading with Xencor
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xencor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xencor will appreciate offsetting losses from the drop in the long position's value.Moving together with Xencor Stock
| 0.67 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
Moving against Xencor Stock
| 0.91 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.81 | DRRX | Durect | PairCorr |
| 0.8 | DTIL | Precision BioSciences | PairCorr |
| 0.79 | VINC | Vincerx Pharma | PairCorr |
The ability to find closely correlated positions to Xencor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xencor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xencor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xencor Inc to buy it.
The correlation of Xencor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xencor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xencor Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xencor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.